Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Clinical trial NCT01458392 · COMPLETED
Trial details
- NCT number
- NCT01458392
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-10-01
- Primary completion
- 2015-06-01
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.